Anti-CD40 Antibody - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Anti-CD40 Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD40 Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anti-CD40 Antibody: Overview
CD40 is a 48?kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. It is also found on a large portion of melanomas and carcinomas of the lung, breast, colon, prostate, pancreas, kidney, ovary, and head and neck as well as all of B cell malignancies (1–4). The ligand for CD40 (CD154 or CD40L) is expressed on activated T cells and platelets.
Function - The protein receptor encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been found to be essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation.[5] AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions.
Anti-CD40 Antibody - CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells. Agonistic CD40 antibodies have been shown to substitute for T cell help provided by CD4+ lymphocytes in murine models of T cell-mediated immunity.
Anti-CD40 Antibody Emerging Drugs Chapters
This segment of the Anti-CD40 Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD40 Antibody Emerging Drugs
Further product details are provided in the report……..
Anti-CD40 Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD40 Antibody drugs segregated based on following parameters that define the scope of the report, such as:
Anti-CD40 Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD40 Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD40 Antibody drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Anti-CD40 Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD40 Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anti-CD40 Antibody: Overview
CD40 is a 48?kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. It is also found on a large portion of melanomas and carcinomas of the lung, breast, colon, prostate, pancreas, kidney, ovary, and head and neck as well as all of B cell malignancies (1–4). The ligand for CD40 (CD154 or CD40L) is expressed on activated T cells and platelets.
Function - The protein receptor encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been found to be essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation.[5] AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions.
Anti-CD40 Antibody - CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells. Agonistic CD40 antibodies have been shown to substitute for T cell help provided by CD4+ lymphocytes in murine models of T cell-mediated immunity.
Anti-CD40 Antibody Emerging Drugs Chapters
This segment of the Anti-CD40 Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD40 Antibody Emerging Drugs
- ABBV-927: AbbVie
- GEN1042: Mirati Therapeutics
- Sotigalimab: Apexigen
Further product details are provided in the report……..
Anti-CD40 Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD40 Antibody drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anti-CD40 Antibody
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Anti-CD40 Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD40 Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD40 Antibody drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD40 Antibody R&D. The therapies under development are focused on novel approaches for Anti-CD40 Antibody.
- Anti-CD40 Antibody Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anti-CD40 Antibody drugs?
- How many Anti-CD40 Antibody drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD40 Antibody?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD40 Antibody therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD40 Antibody and their status?
- What are the key designations that have been granted to the emerging drugs?
- AbbVie
- Genmab
- Apexigen
- Kiniksa Pharmaceuticals
- Eledon Pharmaceuticals
- Seagen
- Celldex
- Eucure Biopharma
- Glycotope
- Biogen
- Astellas Pharma
- Kyowa Kirin
- Boston Immune Technologies and Therapeutics
- Bristol-Myers Squibb
- ABBV-927
- GEN 1042
- Sotigalimab
- KPL 404
- AT-1501
- SEA-CD40
- CDX-1140
- YH003
- CD40-GEX
- Dapirolizumab pegol
- Bleselumab
- BITD 401412
- BMS 986325
Introduction
Executive Summary
Anti-CD40 Antibody: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD40 Antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD40 Antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD40 Antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Dapirolizumab pegol: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Sotigalimab : Apexigen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
GEN 1042: Genmab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BITD 401412: Boston Immune Technologies and Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD40 Antibody Key Companies
Anti-CD40 Antibody Key Products
Anti-CD40 Antibody- Unmet Needs
Anti-CD40 Antibody- Market Drivers and Barriers
Anti-CD40 Antibody- Future Perspectives and Conclusion
Anti-CD40 Antibody Analyst Views
Anti-CD40 Antibody Key Companies
Appendix
Executive Summary
Anti-CD40 Antibody: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD40 Antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD40 Antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD40 Antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Dapirolizumab pegol: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Sotigalimab : Apexigen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
GEN 1042: Genmab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BITD 401412: Boston Immune Technologies and Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD40 Antibody Key Companies
Anti-CD40 Antibody Key Products
Anti-CD40 Antibody- Unmet Needs
Anti-CD40 Antibody- Market Drivers and Barriers
Anti-CD40 Antibody- Future Perspectives and Conclusion
Anti-CD40 Antibody Analyst Views
Anti-CD40 Antibody Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anti-CD40 Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anti-CD40 Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anti-CD40 Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anti-CD40 Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
